Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Ocrelizumab in Relapsing Multiple Sclerosis
NCT05834855Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2023
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in multiple sclerosis (MS), sponsored by Amsterdam University Medical Center. Started Apr 2023; status: recruiting.
02
Drugs
rituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05834855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05834855.